Mithra Signs License and Supply Agreement with Mayne Pharma for Commercialization of Estelle in Australia

  • Consolidation of partnership with Mayne Pharma for commercialization of the combined oral contraceptive E4/DRSP (Estelle®) in Australia
  • Mithra eligible for milestone and license fees of up to EUR 3.5 million
  • Preparation ongoing for the commercial launch of Mithra’s oral contraceptive in the U.S. and Australia, targeted for H1 and H2 2021 respectively

Liege, Belgium, 28 May 2020 – 8:15 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces it has entered into an exclusive 20-year license and supply agreement with Mayne Pharma Group Limited (“Mayne”) for the commercialization of its combined oral contraceptive E4/DRSP (Estelle) in Australia.

Mithra Launches a Research Programme on Estetrol’s Effect in Covid-19 Treatment

  • Women are more likely than men to be spared by Covid-19, with less severe infections and lower mortality rates
  • Protective role of estrogen against human coronaviruses already demonstrated during the SARS infection, and currently being tested in the U.S. among hospitalized patients
  • Mithra plans to develop a research program to study Estetrol (E4) mechanism of action in the treatment of Covid-19.

Liège, Belgium, 25 May 2020 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces its intention to launch a Phase II study program to assess the potential beneficial effect of Estetrol (E4) on Covid-19 infection. E4 is a naturally occurring estrogen produced by the liver of the human fetus, passing in maternal blood at relatively high levels during pregnancy.

Mithra and Searchlight Pharma Announce Filing of New Drug Submission for Estelle® in Canada

  • Searchlight Pharma’s New Drug Submission for a novel combined oral contraceptive (COC) accepted for review by Health Canada
  • Innovative product candidate developed by Mithra containing the unique native estrogen Estetrol (E4) and drospirenone (DRSP)
  • Potential commercialization in Canada under the trademark Nextstellis® expected in mid 2021

LIEGE (Belgium) and MONTREAL (Canada), 20 May 2020 – 7:30 CEST – Mithra and Searchlight Pharma announced today that Health Canada has accepted Searchlight Pharma’s New Drug Submission (“NDS”) for a novel combined oral contraceptive (COC) product.

Mithra and Gynial Sign Commercialization Agreement for Myring™ in Switzerland

  • Mithra grants license for its vaginal contraceptive ring to Gynial for commercialization in Switzerland
  • Strengthening its partnership with Women’s Health specialist Gynial, already responsible for the Austrian market
  • Large-scaled global commercialization of Myring™ after first successful launches in Europe

Liege, Belgium, 05 May 2020 – 7 :30  CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces that it has entered into a license and supply agreement (LSA) with Gynial GmbH for the commercialization of its hormonal contraceptive ring Myring™ in Switzerland.